---
layout: default
title: Denosumab
parent: 僅模型預測 (L5)
nav_order: 105
evidence_level: L5
indication_count: 2
---

# Denosumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Denosumab: From Unspecified Original Indication to Severe Nonproliferative Diabetic Retinopathy

## One-Sentence Summary

> Denosumab is a RANKL-targeted monoclonal antibody; this evidence pack does not contain data on its original approved indication or mechanism of action (data gaps DG001/DG002).
> The TxGNN model predicts potential efficacy for **Severe Nonproliferative Diabetic Retinopathy**,
> but currently **no clinical trials** and **no literature** support this specific direction.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in evidence pack (original MOA and indication data are both flagged as data gaps — see DG001/DG002) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Market Status (Taiwan) | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for denosumab in this evidence pack (DG002, High severity). Without confirmed original indication or MOA data, no direct mechanistic bridge can be established to severe nonproliferative diabetic retinopathy (NPDR).

The repurposing rationale notes that the OPG/RANKL/RANK signaling axis has been theoretically associated with vascular endothelial dysfunction and pathological angiogenesis, which are relevant to diabetic microvascular disease. However, this link is speculative — it is not derived from any training data, clinical trial, or publication specific to severe NPDR. The 0.996 TxGNN score reflects graph-neural-network connection strength only, not clinical or mechanistic validation.

Given the missing MOA and original indication data, this prediction should be treated as a pure hypothesis-generation signal rather than a mechanistically substantiated candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| — | — | — | No authorizations on record (0 licenses; not marketed) |

---

## Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug interaction data are all currently unavailable — DG001, Blocking severity, must be resolved via TFDA label retrieval before any safety assessment can proceed.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests solely on a TxGNN connectivity score (L5) with zero supporting clinical trials or literature, and two unresolved data gaps — missing TFDA label/safety data (Blocking) and missing MOA (High) — prevent even a preliminary S1 safety evaluation.

**To proceed, the following is needed:**
- TFDA package insert (warnings, contraindications) — DG001, blocking
- Denosumab mechanism of action data from DrugBank — DG002
- Original approved indication(s) to establish original-to-new indication rationale
- Disease-specific (severe NPDR) clinical or preclinical evidence; note that the broader "diabetic retinopathy" category (rank 2, score 0.992) already has L4 evidence (1 Phase 3 trial, 2 publications) and may be a more tractable starting point for further investigation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

